Articles On Immutep (ASX:IMM)

The ASX is set to open modestly higher on Tuesday China is set to benefit from a possible US default as debt ceiling deadline looms US lawmakers urged to stick to categorising cryptos as securities, not commdities   The ASX is set to open...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Immutep (ASX IMM) has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate a new investigator-initiated trial of eftilagimod alpha.

The ASX is expected to open higher on a new week after gains continued across New York on Friday night in the aftermath of quarterly reporting season. Elsewhere, eyes are fixated on central banks across the world this week, with the RBA...

The ASX is poised to open higher on Monday, tracking Wall Street’s moves ExxonMobil reports record profits The Fed and RBA will make rates decisions this week   The ASX is poised to open higher on Monday, tracking Friday’s gains in New Yo...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The ASX is on Thursday expected to follow the US Dow Jones index, which declined overnight following another slump in the banking sector. The dip comes from troubles surrounding the First Republic Bank, which has seen its shares fall mor...

Immutep (ASX:IMM) has announced the initiation of the AIPAC-003 Phase 2/3 clinical trial of its eftilagimod alpha in combination with paclitaxel for treating metastatic HER2-neg/low breast cancer.

ShareCafeLake Resources leads the way as ASX closes 0.27% higher by Peter Milios   At the closing bell, the S&P/ASX 200 was 0.27 per cent higher at 7,381.50, led by gains in the financials and real estate sectors. Lake Resources (ASX:LK...

ShareCafeTech leaders gain as ASX rises 0.3% at noon by Peter Milios   At noon, the S&P/ASX 200 is 0.30 per cent higher at 7,383.60. Nine out of the eleven sectors are trading higher today. Information technology is surging on the back...

ShareCafeStocks of the Hour: SYA, ALA, LKE, IMM                    On Friday, Sayona Mining (ASX:SYA) announced an update on their Definitive Feasibility Study confirming the North American Lithium operation with an NPV of A$2.2 billi...

17 Apr 2023 - A snapshot of the stocks on the move featuring Sayona Mining (ASX:SYA), Arovella Therapeutics (ASX:ALA), Lake Resources (ASX:LKE) and Immutep (ASX:IMM).

The ASX is expected to rise on a fresh week, with eyes on US earnings as companies prepare to report this week. Ahead of a new week and market opening in Australia, here are some ASX-listed companies to look out for during Monday’s trade...

Dr Boreham’s Crucible: Radiopharm Theronostics By Tim Boreham ASX code: ((RAD)); NASDAQ code (proposed): RADX Share price: 14.5 cents Market cap: $49.15 million Shares on issue: 238,947,639 (100,000,000 more in ASX escrow) Chief executive o...

Immutep (ASX:IMM), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, has announced that Lis Boyce has been appointed as a non-executive director.

ShareCafeGains from materials and healthcare boost ASX 0.71% at noon by Peter Milios   At noon, the S&P/ASX 200 is 0.71 per cent higher at 7,172.90, with materials and healthcare sectors leading the gains. Syrah Resources (ASX:SYR), Blo...

31 Mar 2023 - A snapshot of the stocks on the move featuring NOVONIX (ASX:NVX), Immutep Limited (ASX: IMM; NASDAQ:IMMP) and Sayona Mining (ASX:SYA).

ShareCafeStocks of the Hour: NVX, IMM, SYA                    NOVONIX (NASDAQ:NVX, ASX:NVX) announced that it has agreed to establish a joint venture with TAQAT to develop and produce anode materials for electric vehicle and energy st...

ShareCafeASX falls 1.4% to three-month low by Peter Milios   At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the collapse of U...

ShareCafeASX down 1.91% at noon to lowest point since Jan by Peter Milios   Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of...

14 Mar 2023 - A snapshot of the stocks on the move featuring Patrys (ASX:PAB), Mt Monger Resources (ASX:MTM) and Immutep (ASX:IMM).

ShareCafeStocks of the Hour: PAB, MTM, IMM                    Patrys (ASX:PAB) has announced that their preclinical data supports synthetic lethality mechanisms to treat relevant cancers. Patrys Chief Executive Officer and Managing Di...

Immutep (ASX:IMM) has announced the initiation of the AIPAC-003 clinical trial evaluating its eftilagimod alpha in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer.

ShareCafeThe Week that Was: February 27-March 3, 2023 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to...

ShareCafeImmutep (ASX: IMM) Delivering Strong Lung Cancer Data Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.   Tim McGowen: We’re talk...

ShareCafeImmutep (ASX: IMM) – Webinar Presentation Marc Voigt – Executive Director & CEO – Immutep is a leading biotechnology company focused on developing effective autoimmune and cancer immunotherapy treatments such as Lag-3. Immutep...

ShareCafeWebinar Recap – Shaw and Partners, IMM, RAD, PET & IMD Catch up on the full webinar Shaw and Partners, Immutep (ASX: IMM), Radiopharm Theranostics (ASX: RAD), Phoslock Environmental Technologies (ASX: PET) & Imdex (ASX: IM...

Australian clinical-stage biotechnology company Immutep (ASX:IMM) has announced that the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with first-line Non-small cell lung cancer.

ShareCafeProperty sector leads ASX 0.3% lower by Peter Milios   Large property players Goodman Group (ASX:GMG), Dexus (ASX:DXS), Mirvac Group (ASX:MGR) and Charter Hall (ASX:CHC) have all suffered losses in today’s session. The index has re...

ShareCafeASX 0.1% lower at noon after all US indices fell over the weekend by Peter Milios   At noon, the S&P/ASX 200 is 0.1 per cent lower at 7,549.20. All sectors besides Energy and Materials are trading lower today, after the US sect...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

ShareCafeIron ore surge not enough to lift the ASX: Aus shares close 0.16% lower by Peter Milios   Iron ore prices have reached a seven-month high due to increased demand expectations from China after its reopening following a Covid-19 surg...

ShareCafeASX down 0.15% at noon despite spike in US markets by Peter Milios   The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

The ASX will open higher this morning, defying a slump in New York Tesla shares plunged 12% Oil prices tumbled on recession fears   Aussie shares are set to open higher this morning despite a fall in New York. At 8am AEDT, the ASX 200 Jan...

Immutep (IMM) completes 50 per cent of patient enrolment for its TACTI-003 phase IIb trial The trial is designed to evaluate Immutep’s first-in-class soluble LAG-3 protein, efti, in combination with KEYTRUDA as first line treatment of re...

Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p...

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Weekly broker wrap: insurers more resilient, healthcare picks, contractors remain labour-reliant, classifieds look resilient, retail braces for decline. -Climate resilience supports domestic insurance outlook-Wilsons lists healthcare sector...

ShareCafeLithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower by Peter Milios   Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the...

ShareCafeLithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon by Lauren Hayes   The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fe...

Immutep (IMM) achieves commercial scale manufacturing of its lead product candidate, eftilagimod alpha (efti)The company completed its first 2000-litre manufacturing run of efti, a first-in-class soluble LAG-3 proteinImmutep has been workin...

Imagion presents positive data at world leading symposium Osteopore expands in Southeast Asia Microba expands into Italy and Portugal   Imagion speaks at world-leading breast cancer symposium Imagion Biosystems (ASX:IBX) is set to rise ov...

ShareCafeShares dip following rate hike: ASX closes 0.5% lower by Peter Milios   The ASX has closed 0.47 per cent lower after the Reserve Bank of Australia delivered its eighth interest rate hike in a row, lifting the cash rate 25 basis hig...

ShareCafeLocal market awaits RBA rate decision: ASX falls 0.17% at noon by Lauren Hayes   The Australian market has followed Wall Street’s negative lead overnight after US markets sold off on fears that the Fed will keep increasing interest...

Well, it’s rates day here in Oz, and property owners are donning their brownest pants for a likely rise. Some say 50bps is sensible. In the US, the Fed got a case to keep rising rates despite the inflationary slowdown. Stronger than expecte...

ShareCafeThe Week that Was: November 28-December 2, 2022 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

ASX Health sector is continuing its upward trend, marginally up this week 0.87%  Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e...

ShareCafeIron ore climbs to highest price since September: ASX closes 0.3% higher by Peter Milios   Singaporean iron ore futures have soared above the US$100 per tonne for the first time since September, resulting in gains for ASX-listed ir...

Immutep (IMM) signs another collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a phase one clinical studyThe companies will conduct and jointly fund the INSIGHT-005 trial in Germany to evaluate Immutep’s efti product...